Histogenics and FDA Conclude Discussions Regarding NeoCart Phase 3 Clinical Trial Data and Regulatory Pathway
Histogenics and FDA Continue to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart in Patients With Knee Cartilage Damage
Walker Lane Resources: Advancing High-grade Gold, Silver assets in North America’s Prolific Regions
Cartier Resources Closes Offering with Paradigm Capital and Concurrent Offering for Aggregate Gross Proceeds of $11,398,596